2024 Archives - Ryvu Therapeutics

June 14, 2024

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Read More

May 15, 2024

Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update

Read More

May 14, 2024

Ryvu Therapeutics to present clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

Read More

April 10, 2024

Ryvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Read More

March 13, 2024

Ryvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Update

Read More

March 6, 2024

Ryvu Therapeutics Announces Disbursement of First Tranche of EUR 8 Million Venture Debt from the European Investment Bank  

Read More

March 6, 2024

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Read More

February 14, 2024

Ryvu Announces Dosing of the First Patient in the RIVER-52 Phase II Study of RVU120 as a Monotherapy for the Treatment of Patients with Relapsed/Refractory AML and HR-MDS

Read More

January 31, 2024

Ryvu Announces Dosing of the First Patient in the RIVER-81 Phase II Study of RVU120 in Combination with Venetoclax for the Treatment of Patients with Relapsed/Refractory AML

Read More

January 4, 2024

Ryvu Therapeutics participates in the upcoming 13th Annual LifeSci Partners Corporate Access Event

Read More